Smallpox vaccine gets funding from U.S. gov't for PhIII; Vaccine data to be presented as ASCO;

> Bavarian Nordic has received an extra $32 million from the U.S. government, which will support the Phase III trials of its smallpox vaccine, IMVAMUNE. Press release | Article

> AE37 breast cancer vaccine data will be presented at ASCO 2012. Press release

> Bavarian Nordic plans to present its PROSTVAC data at ASCO, too. Press release

> A newly-discovered protein interaction could be a new target for development of a broad-spectrum HPV vaccine. Press release

> A combination of a cancer vaccine and monoclonal antibodies was effective in a mouse model of glioma. Abstract

And Finally… Cancer vaccine company Tvax Biomedical has withdrawn its planned IPO because of "market conditions." Article

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.